glp-1 egfr cut off Diabetic kidney disease: a new era in therapeutic management Preventing diabetic kidney disease progression

Eli Lillys tirzepatide uses synthetic versions of GLP-1 and gastric inhibitory polypeptide

Emerging preclinical and clinical trials suggest synthetic GLP-1 drugs interact with dopamine and serotonin pathways to decrease depression and improve ones mood

The high monthly cost of these medications poses a significant barrier, particularly in resource-limited settings

Platelet-rich plasma (PRP) injections and red-light therapy may also speed up recovery by stimulating hair follicles, though evidence is limited

The authors found that GLP-1 RA use was associated with a significantly decreased risk of developing dry AMD compared with patients taking metformin (HR = .68), insulin (HR = .72), and statins (HR = .70)